Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.37 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 2/20 | 0.37 |
| ▸ | SI | P14410 | 2/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9538568 | 1.00 | TSHR (0.40) | TSHRSLC1A1KDM4ELMNAMGAM | |
| Hydrochloric Acid SCHEMBL8968568 | 1.00 | TSHR (0.40) | TSHRSLC1A1KDM4ELMNAMGAM | |
| Hydrochloric Acid SCHEMBL9538572 | 1.00 | TSHR (0.40) | TSHRSLC1A1KDM4ELMNAMGAM | |
| Hydrochloric Acid SCHEMBL1802201 | 1.00 | TSHR (0.40) | TSHRSLC1A1KDM4ELMNAMGAM | |
| SCHEMBL12286780 | 0.98 | TSHR (0.42) | TSHRSLC1A1KDM4ELMNAMGAM | |
| SCHEMBL196759 | 0.98 | TSHR (0.42) | TSHRSLC1A1KDM4ELMNAMGAM | |
| SCHEMBL196760 | 0.98 | TSHR (0.42) | TSHRSLC1A1KDM4ELMNAMGAM | |
| Iodide SCHEMBL17393001 | 0.95 | TSHR (0.40) | TSHRSLC1A1KDM4ELMNAMGAM | |
| Ethylene Glycol SCHEMBL27903479 | 0.91 | TSHR (0.37) | TSHRSLC1A1KDM4ELMNAMGAM | |
| SCHEMBL25491243 | 0.88 | SLC1A1 (0.35) | TSHRSLC1A1KDM4ELMNAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116903483-B | Amino acid surfactant, and preparation method and application thereof | 中国石油大学(华东) | 2025-05-30 | — | — | CN | claimed |
| CN-119409588-A | Caffeoyl amino acid methyl ester derivative and preparation method and application thereof | 西北大学 | 2025-02-11 | — | — | CN | claimed |
| CN-119264465-A | Method for stabilizing high internal phase oil-in-water emulsion by crosslinking phenylalanine-aspartic acid copolymer and polylysine ions | 江南大学 | 2025-01-07 | — | — | CN | claimed |
| CN-119241617-A | 2 '-Deoxy-2' -fluoro-N4-substituted cytidine compound, preparation method and application thereof | 河南省科学院高新技术研究中心 | 2025-01-03 | — | — | CN | claimed |
| CN-119192087-A | Chemical synthesis method of ergothioneine | 镇江卡博医药科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-114807200-B | Carrier-free double-immobilized biocatalyst with surface displaying biological enzyme and preparation method and application thereof | 大连理工大学 | 2024-07-16 | — | — | CN | claimed |
| CN-116903483-A | Amino acid surfactant, and preparation method and application thereof | 中国石油大学(华东) | 2023-10-20 | — | — | CN | claimed |
| CN-113527399-B | Ginsenoside CK derivative and application thereof in preparation of antitumor drugs | 陕西巨子生物技术有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-113527399-A | Ginsenoside CK derivative and application thereof in preparation of antitumor drugs | 陕西巨子生物技术有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-212139382-U | Novel swimsuit with skirt hem | 晋江咏咏服装有限公司 | 2020-12-15 | — | — | CN | claimed |
| CN-108496964-A | Citrus method for producing insecticide | 金华市铁骑士生物科技有限公司 | 2018-09-07 | — | — | CN | claimed |
| US-12577213-B2 | Deuterated 1,4-benzodiazepine-2,5-dione compound and use thereof | Ningbo Combireg Pharmaceutical Technology Co., Ltd. (CN) | 2026-03-17 | — | — | US | disclosed |
| CN-121471290-A | Synthesis method of N-goose deoxycholate-L-aspartic acid and application of N-goose deoxycholate-L-aspartic acid in preparation of medicines for improving metabolism-related fatty liver disease | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | 2026-02-06 | — | — | CN | disclosed |
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2025-07-15 | — | — | US | disclosed |
| WO-2025137293-A2 | ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS | Roche Sequencing Solutions, Inc. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-0204440-A1 | Azetidine derivatives production | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1986-12-10 | — | — | EP | disclosed |
| EP-0168831-A2 | Tetrapyrrole compounds and process for the production of same and a pharmaceutical composition containing same | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1986-01-22 | — | — | EP | disclosed |
| EP-0168832-A2 | Pharmaceutical composition containing a tetrapyrrole compound as active ingredient and process for the production of the tetrapyrrole compound | Nippon Petrochemicals Co., Ltd. (JP) | 1986-01-22 | — | — | EP | disclosed |
| EP-0144840-A2 | Optically active beta-lactams and method of their production | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
| US-3948971-A | N-protected-α-amino acid compounds | MERCK & CO., INC. (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | IL2, THPO, IL6 | GAA 2994/4885CA2 2324/4885TSHR 4631/4885 |
| US-12577213-B2 | Deuterated 1,4-benzodiazepine-2,5-dione compound and use thereof | HSD3B1, CYP11B1, CYP2E1 | GAA 3932/4885CA2 1837/4885TSHR 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.